Zaltrap
Zaltrap (ziv-aflibercept) is a recombinant fusion protein medication used to treat metastatic colorectal cancer. It works as an angiogenesis inhibitor by blocking vascular endothelial growth factor (VEGF) pathways, preventing the formation of new blood vessels that tumors need to grow. This medication is typically used in combination with chemotherapy (FOLFIRI regimen) for patients whose cancer has progressed after treatment with oxaliplatin-based chemotherapy.
Zaltrap is an anti-angiogenesis drug used with chemotherapy to treat metastatic colorectal cancer by blocking blood vessel formation to tumors.
Key facts at a glance
- RxNorm
- 1304480
- Generic
- Zaltrap
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Zaltrap is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) that has progressed following oxaliplatin-based chemotherapy. It is used in combination with FOLFIRI (fluorouracil, leucovorin, and irinotecan) chemotherapy.
Zaltrap is a fusion protein composed of vascular endothelial growth factor (VEGF) receptor extracellular domains fused to the Fc portion of human IgG1. It acts as a VEGF trap that binds to VEGF-A, VEGF-B, and placental growth factor (PlGF), preventing these growth factors from activating their receptors. By blocking angiogenesis (new blood vessel formation), it inhibits tumor growth and spread.
Zaltrap is administered as an intravenous infusion every two weeks. Common side effects include hypertension, fatigue, diarrhea, and proteinuria. It carries warnings for severe hypertension, bleeding, gastrointestinal perforation, and impaired wound healing. Patients should be monitored closely for signs of these complications. This medication should only be administered under the supervision of a qualified oncologist.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy